| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Observational Study |
| Article Title |
Safety and efficacy of tenofovir in chronic hepatitis B-related decompensated cirrhosis
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Soon Kyu Lee, Myeong Jun Song, Seok Hyun Kim, Byung Seok Lee, Tae Hee Lee, Young Woo Kang, Suk Bae Kim, Il Han Song, Hee Bok Chae, Soon Young Ko and Jae Dong Lee |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Catholic Medical Center Research Foundation program in 2014 |
5-2014-B0001-00176 |
|
| Corresponding Author |
Myeong Jun Song, MD, PhD, Division of Hepatology, Department of Internal Medicine, Daejeon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Daeheung-ro 64, Jung-gu, Daejeon 34943, South Korea. mjsong95@gmail.com |
| Key Words |
Tenofovir; Decompensated liver cirrhosis; Compensated liver cirrhosis; Virological response; Renal safety |
| Core Tip |
We evaluated the safety and efficacy of disoproxil fumarate (TDF) treatment in patients with treatment-naïve chronic hepatitis B related decompensated cirrhosis. TDF therapy for 12 mo in decompensated cirrhosis patients was effective for decreasing hepatitis B virus DNA levels and improving hepatic function with relatively lower complete virological response (CVR) than in compensated cirrhosis (70.2% vs 88.9%). The elevation of serum creatinine (> 0.5 mg/dL) in the decompensated cirrhosis relatively higher compared to compensated cirrhosis patients (7.0% vs 2.5%, respectively, P < 1.000). Therefore, TDF therapy is useful in decompensated cirrhosis and needed for close monitoring of CVR and renal function. |
| Publish Date |
2017-04-06 18:30 |
| Citation |
Lee SK, Song MJ, Kim SH, Lee BS, Lee TH, Kang YW, Kim SB, Song IH, Chae HB, Ko SY, Lee JD. Safety and efficacy of tenofovir in chronic hepatitis B-related decompensated cirrhosis. World J Gastroenterol 2017; 23(13): 2396-2403 |
| URL |
http://www.wjgnet.com/1007-9327/full/v23/i13/2396.htm |
| DOI |
http://dx.doi.org/10.3748/wjg.v23.i13.2396 |
